LeMaitre Vascular (NASDAQ:LMAT) Cut to “Hold” at StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other analysts also recently commented on LMAT. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Down 0.7 %

NASDAQ:LMAT opened at $100.28 on Friday. LeMaitre Vascular has a 52-week low of $52.79 and a 52-week high of $109.58. The stock has a fifty day simple moving average of $97.47 and a 200-day simple moving average of $89.33. The company has a market capitalization of $2.25 billion, a PE ratio of 54.80, a price-to-earnings-growth ratio of 2.48 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the company posted $0.33 EPS. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Several institutional investors and hedge funds have recently bought and sold shares of the company. Conestoga Capital Advisors LLC increased its holdings in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after acquiring an additional 36,850 shares during the last quarter. Copeland Capital Management LLC boosted its holdings in LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after purchasing an additional 11,318 shares during the period. State Street Corp increased its stake in LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after purchasing an additional 28,525 shares during the last quarter. Congress Asset Management Co. raised its holdings in shares of LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock worth $65,888,000 after purchasing an additional 18,295 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of LeMaitre Vascular by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock worth $50,403,000 after buying an additional 23,443 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.